Summary
The effects of piracetam on dopamine metabolism in rat striatal tissue and on behavioural and biochemical effects of haloperidol were studied. Piracetam in doses 600 mg/kg and 1,000 mg/kg (i.p.) increased the levels of dopamine metabolites (homovanillic acid and 3,4-dihydroxy-phenylacetic acid) but did not influence the content of dopamine in the striatum. Piracetam (1,000 mg/kg) also increased haloperidol-induced catalepsy in rats. These results are discussed in relation to the hypothesis that some behavioural effects of piracetam can be connected with its action on dopaminergic transmission.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Beger PA, Elliot GR, Barchas ID (1978) Neuroregulators and schizophrenia. In: Lipton MA, Maxio AD, Killam KF (eds) Psychopharmacology: A generation of progress. Raven Press, New York, pp 1071–1082
Binder S (1977) Piracetam und die Behandlung chronisch Alkoholkranker. In: Proceedings of Symposium on Nootropil. Praha —Bratislava, pp. 87–100
Earley GI, Leonard BE (1978) Isolation and assay of noradrenaline, dopamine, 5-hydroxytryptamine, and several metabolites from brain tissue using disposable Bio-Rad columns packed with Sephadex G-10. J Pharmacol Meth 1:67–79
Kabeš J, Erban L, Hanzliček L, Skondia V (1979) Biological correlates of piracetam clinical effects in psychotic patients. J Int Med Res 7:277–284
Lizuka J (1978) Piracetam in der modernen Pharmakotherapie des Parkinson-Syndroms. Med Welt 29:1381–1388
Lloyd-Evans S, Brocklenhurst IC, Palmer MK (1979) Piracetam in chronic brain failure. Curr Med Opin 6:351–357
Nybäck H, Wiesel F-A, Skett P (1979) Effects of piracetam on brain monoamine metabolism and serum prolactin levels in the rat. Psychopharmacology 61:235–238
Skondia V (1979) In: Criteria for clinical development and classification of nootropic drugs. An example: piracetam. 21. Annual Czechoslovak Psychopharmacological Meeting, Jesenik Spa, pp 40–54
Stegink AI (1972) The clinical use of pracetam a new nootropic drug. The treatment of symptoms of senile involution. Arzneim-Forsch 22:975–977
Waldmeier PC, Delini-Stula AA (1979) Serotonin-dopamine interactions in the nigrostriatal system. Eur J Pharmacol 55:363–373
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rägo, L.K., Allikmets, L.H. & Zarkovsky, A.M. Effects of piracetam on the central dopaminergic transmission. Naunyn-Schmiedeberg's Arch. Pharmacol. 318, 36–37 (1981). https://doi.org/10.1007/BF00503309
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00503309